GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

2024 — A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a new ... Researchers Develop Analytical Pipeline to Identify ...

Aerobic exercise has been linked with Parkinson's disease progression and risk. (Washington Post) Air purifiers in ...

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study  examined the ...

The University of Pittsburgh was awarded $8 million to continue researching a new therapy for Parkinson's patients.

KinCon biolabs, a spin-off from the University of Innsbruck, is expanding its patented platform technology to support ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

offering a new therapeutic target for Parkinson's and other movement ... Some Diabetes Drugs Tied to Lower Risk of Dementia, Parkinson's Disease Sep. 18, 2024 — A class of drugs for diabetes may ...